AC Immune
ACIU
About: AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Employees: 172
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 12
3% more capital invested
Capital invested by funds: $48.5M [Q1] → $49.7M (+$1.27M) [Q2]
0% more funds holding
Funds holding: 41 [Q1] → 41 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
1.79% less ownership
Funds ownership: 26.2% [Q1] → 24.4% (-1.79%) [Q2]
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $93K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
BTIG
Thomas Shrader
|
$8
|
Buy
Reiterated
|
8 Sep 2025 |
Financial journalist opinion
